ACA/Obamacare – APRA https://www.americanpatient.org American Patient Rights Association Thu, 03 Jul 2025 23:57:34 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://www.americanpatient.org/wp-content/uploads/2018/07/favicon-APRA1-150x150.png ACA/Obamacare – APRA https://www.americanpatient.org 32 32 Preventive Care May Be Free, but Follow-Up Diagnostic Tests Can Bring Big Bills https://www.americanpatient.org/preventive-care-may-be-free-but-follow-up-diagnostic-tests-can-bring-big-bills/?utm_source=rss&utm_medium=rss&utm_campaign=preventive-care-may-be-free-but-follow-up-diagnostic-tests-can-bring-big-bills https://www.americanpatient.org/preventive-care-may-be-free-but-follow-up-diagnostic-tests-can-bring-big-bills/#respond Mon, 25 Jul 2022 21:37:15 +0000 https://www.americanpatient.org/?p=59440 Read More]]> Article Summary: Preventive screenings like mammograms may be free, but follow-up tests can be expensive to patients seeking further treatments.

By Michelle Andrews, KHN.

When Cynthia Johnson learned she would owe $200 out-of-pocket for a diagnostic mammogram in Houston, she almost put off getting the test that told her she had breast cancer.

“I thought, ‘I really don’t have this to spend, and it’s probably nothing,’” said Johnson, who works in educational assessment at a university. But she decided to go forward with the test because she could put the copay on a credit card.

Johnson was 39 in 2018 when that mammogram confirmed that the lump she’d noticed in her left breast was cancer. Today, after a lumpectomy, chemotherapy, and radiation, she is disease-free.

Having to choose between paying rent and getting the testing they need can be a serious dilemma for some patients. Under the Affordable Care Act, many preventive services — such as breast and colorectal cancer screening — are covered at no cost. That means patients don’t have to pay the normal copayments, coinsurance, or deductible costs their plan requires. But if a screening returns an abnormal result and a health care provider orders more testing to figure out what’s wrong, patients may be on the hook for hundreds or even thousands of dollars for diagnostic services.

Many patient advocates and medical experts say no-cost coverage should be extended beyond an initial preventive test to imaging, biopsies, or other services necessary for diagnosing a problem.

“The billing distinction between screening and diagnostic testing is a technical one,” said Dr. A. Mark Fendrick, director of the University of Michigan’s Center for Value-Based Insurance Design. “The federal government should clarify that commercial plans and Medicare should fully cover all the required steps to diagnose cancer or another problem, not just the first screening test.”

A study that examined more than 6 million commercial insurance claims for screening mammograms from 2010 to 2017 found that 16% required additional imaging or other procedures. Half the women who got further imaging and a biopsy paid $152 or more in out-of-pocket costs for follow-up tests in 2017, according to the study by Fendrick and several colleagues and published by JAMA Network Open.

People who needed testing after other preventive cancer screenings also racked up charges: half paid $155 or more for a biopsy after a suspicious result on a cervical cancer test; $100 was the average bill for a colonoscopy after a stool-based colorectal cancer test; and $424, on average, was charged for follow-up tests after a CT scan to check for lung cancer, according to additional research by Fendrick and others.

Van Vorhis of Apple Valley, Minnesota, did an at-home stool test to screen for colorectal cancer two years ago. When the test came back positive, the 65-year-old retired lawyer needed a follow-up colonoscopy to determine whether anything serious was wrong.

The colonoscopy was unremarkable: It found a few benign polyps, or clusters of cells, that the physician snipped out during the procedure. But Vorhis was floored by the $7,000 he owed under his individual health plan. His first colonoscopy several years earlier hadn’t cost him a cent.

He contacted his doctor to complain that he hadn’t been warned about the potential financial consequences of choosing a stool-based test to screen for cancer. If Vorhis had chosen to have a screening colonoscopy in the first place, he wouldn’t have owed anything because the test would have been considered preventive. But after a positive stool test, “to them it was clearly diagnostic, and there’s no freebie for a diagnostic test,” Vorhis said.

He filed an appeal with his insurer but lost.

In a breakthrough for patients and their advocates, people who are commercially insured and, like Vorhis, need a colonoscopy after a positive stool test or a so-called direct visualization test like a CT colonography will no longer face out-of-pocket costs. According to federal rules for health plan years starting after May 31, the follow-up test is considered an integral part of the preventive screening, and patients can’t be charged anything for it by their health plan.

The new rule may encourage more people to get colorectal cancer screenings, cancer experts said, since people can do a stool-based test at home.

Nine states already required similar coverage in the plans they regulate. Arkansas, California, Illinois, Indiana, Kentucky, Maine, Oregon, Rhode Island, and Texas don’t allow patients to be charged for follow-up colonoscopies after a positive stool-based test, according to Fight Colorectal Cancer, an advocacy group. New York recently passed a bill that is expected to be signed into law soon, said Molly McDonnell, the organization’s director of advocacy.

In recent years, advocates have also pushed to eliminate cost sharing for breast cancer diagnostic services. A federal bill that would require health plans to cover diagnostic imaging for breast cancer without patient cost sharing — just as they do for preventive screening for the disease — has bipartisan support but hasn’t made headway.

In the meantime, a handful of states — Arkansas, Colorado, Illinois, Louisiana, New York, and Texas — have moved ahead on this issue, according to tracking by Susan G. Komen, an advocacy organization for breast cancer patients that works to get these laws passed.

This year, an additional 10 states introduced legislation similar to the federal bill, according to Komen. In two of them — Georgia and Oklahoma — the measures passed.

These state laws apply only to state-regulated health plans, however. Most people are covered by employer-sponsored, self-funded plans that are regulated by the federal government.

“The primary pushback we get comes from insurers,” said Molly Guthrie, vice president of policy and advocacy at Komen. “Their argument is cost.” But, she said, there are significant cost savings if breast cancer is identified and treated in its early stages.

A study that analyzed claims data after a breast cancer diagnosis in 2010 found that the average overall costs for people diagnosed at stage 1 or 2 were just more than $82,000 in the year after diagnosis. When breast cancer was diagnosed at stage 3, the average costs jumped to nearly $130,000. For people with a stage 4 diagnosis, costs in the year afterward exceeded $134,000. Disease stages are determined based on tumor size and spread, among other factors.

When asked to provide health plans’ perspective on eliminating cost sharing for follow-up testing after an abnormal result, a spokesperson for a health insurance trade group declined to elaborate.

“Health plans design their benefits to optimize affordability and access to quality care,” David Allen, a spokesperson for AHIP, said in a statement. “When patients are diagnosed with medical conditions, their treatment is covered based on the plan they choose.”

In addition to cancer screenings, dozens of preventive services are recommended by the U.S. Preventive Services Task Force and must be covered without charging patients under the Affordable Care Act if they meet age or other screening criteria.

 

But if health plans are required to cover diagnostic cancer testing without charging patients, will eliminating cost sharing for follow-up testing after other types of preventive screenings — for abdominal aortic aneurysms, for example — be far behind?

Bring it on, said Fendrick. The health system could absorb those costs, he said, if some low-value preventive care that isn’t recommended, such as cervical cancer screening in most women older than 65, were discontinued.

“That is a slippery slope that I really want to ski down,” he said.

Article link

 

[pmpro_levels]
]]>
https://www.americanpatient.org/preventive-care-may-be-free-but-follow-up-diagnostic-tests-can-bring-big-bills/feed/ 0
Avoid These 8 Types of Health Plans, 30 Patient Organizations Say https://www.americanpatient.org/avoid-these-8-types-of-health-insurance-plans-30-patient-organizations-say/?utm_source=rss&utm_medium=rss&utm_campaign=avoid-these-8-types-of-health-insurance-plans-30-patient-organizations-say Tue, 11 May 2021 21:48:32 +0000 https://www.americanpatient.org/?p=27654 Claims Denials and Appeals in ACA Marketplace Plans https://www.americanpatient.org/claims-denials-and-appeals-in-aca-marketplace-plans/?utm_source=rss&utm_medium=rss&utm_campaign=claims-denials-and-appeals-in-aca-marketplace-plans https://www.americanpatient.org/claims-denials-and-appeals-in-aca-marketplace-plans/#respond Sun, 03 Mar 2019 03:49:18 +0000 https://www.americanpatient.org/?p=6834 Read More]]>
By Karen Pollitz, Cynthia Cox Follow and Rachel Fehr, for KFF – Henry J. Kaiser Family Foundation.
.

In this report, we analyze transparency data released by the Centers for Medicare and Medicaid Services (CMS) to examine claims denials and appeals among issuers offering individual market coverage on healthcare.gov from 2015-2017.

We find that, across issuers with complete data, 19% of in-network claims were denied by issuers in 2017, with denial rates for specific issuers varying significantly around this average, from less than 1% to more than 40%.

We also find that consumers rarely appeal claims denials to their issuers, and when they do, issuers typically uphold their original decision. Healthcare.gov consumers appealed less than one-half of one percent of denied claims, and issuers overturned 14% of appealed denials.

Transparency data can provide information about health plan coverage and operations that might not otherwise be readily apparent. For example, they can reveal how often issuers deny claims or pay claims promptly.

Transparency data can also shed light on the adequacy of health plan networks, for example, showing how often enrollees seek out-of-network care. Data can form the basis for report cards or other tools to help consumers understand and compare health plan options, and can inform oversight activities, such as plan certification and market conduct examinations.

ACA Marketplace plans denied an average of nearly 1 in 5 in-network claims in 2017; denial rates ranged from 1% to 45% across insurers

The data posted by CMS has significant limitations, some of which may be partially addressed in future collections. The large range in claim denial rates across issuers raise questions about the quality of the data. The current release does not provide information about why a claim was denied, making it difficult to assess what is driving the denials and why they vary so much. CMS also is not collecting data for several categories specified in the Affordable Care Act (ACA), including the number of out-of-network claims submitted and denied and consumer financial liability for out-of-network claims. In addition, while the law requires reporting by most employer-sponsored group health plans and other individual market plans, CMS is currently only collecting information from issuers offering individual plans through the Federal Marketplace.

ACA Transparency Data

The Affordable Care Act (ACA) requires periodic data reporting by group health plans and by health insurance issuers in the individual and group markets to make more transparent how coverage works in practice.1 Plans are to report data on the following:

  • Claims payment policies and practices
  • Periodic financial disclosures
  • Data on enrollment
  • Data on disenrollment
  • Data on the number of claims that are denied
  • Data on rating practices
  • Information on cost-sharing and payments with respect to any out-of-network coverage
  • Information on enrollee and participant rights under this title
  • Other information as determined appropriate by the Secretary

The law requires these data to be available to state insurance regulators and to the public.

In 2016, the Centers for Medicare and Medicaid Services (CMS) began collecting ACA transparency data for non-group issuers of qualified health plans (QHPs) – both major medical and stand-alone dental plans (SADPs) – sold through healthcare.gov. Currently, public use files for three calendar years – 2017, 2016, and 2015 – are aggregated at the issuer level and available online.

We analyzed these public files, with a particular focus on major medical plans. We excluded issuers that primarily offered stand-alone dental coverage and companies with incomplete data. The working files for this analysis are posted to the report page and the methods section below details our rules for inclusion.

There are limitations to the publicly-posted data. For example, the transparency data do not include reasons for claims denials. Issuers use standardized reason codes for claims adjustments and denials; without this information, one cannot distinguish claims denied for reasons of medical necessity, for example, from those denied due to an incorrect or incomplete submission. Transparency data also do not include other detail that could shed light on the nature of claims submitted and denied – for example, reporting on the types of services or dollar amounts involved.

Additionally, reporting differences may be the result of issuers interpreting instructions differently, particularly around how to report partially approved claims or duplicate claims denied. The accuracy of data reporting may be another limitation; CMS does not conduct data verification of the transparency data.

CMS does not yet require issuers to report data for some categories specified in law, such as the number of out-of-network claims submitted or denied or consumer financial liability for out-of-network claims.2  In addition, although the ACA called for transparency data reporting to begin September 1, 2010 for all non-grandfathered individual and group plans offered outside of the marketplace, to date, the federal government does not collect transparency data for any of the following:

  • Qualified health plans (QHPs) offered through 12 state-based marketplaces
  • Non-group plans offered outside of the marketplace in any state
  • Employer-sponsored health plans (non-grandfathered) offered through or outside of the marketplace in any state

Analysis of Transparency Data

ACA transparency data reveal new information not previously available to the public about the number of in-network claims submitted in healthcare.gov plans, the number of in-network claims denied, the number of denied claims that are appealed, and the outcome of appeals.3 This provides a glimpse into plan performance that may be of interest to consumers and regulators.

Claims submitted and denied

Of the 180 major medical issuers in healthcare.gov states included in the transparency data, 130 show complete data on in-network claims received and denied for the 2017 plan year. Together these issuers reported 229.8 million in-network claims received, of which 42.9 million were denied, for an average in-network claims denial rate of 19%.

In these data, issuers report all denials including denials due to ineligibility, denials due to incorrect submission or billing, duplicate claims, and denials based on medical necessity.

ACA transparency data show denial rates by issuers were highly variable, ranging from 1% to 45% of in-network claims. Overall for 2017, 40 of the 130 reporting Healthcare.gov major medical issuers had a denial rate for in-network claims of 10% or lower. Another 43 reporting issuers denied between 11 and 20% of in-network claims that year, while 47 issuers denied more than 20% of in-network claims this year.

Denial rates also vary from state to state (Figure 3). However, in states where multiple issuers participate in the marketplace, the average denial rate can obscure variation among issuers. For example, in Florida, where six marketplace issuers together denied 11% of more than 40 million in-network claims submitted in 2017, denial rates of the six issuers ranged from 2% to 32%.

A variety of factors could explain the variation in denial rates across issuers and markets , including but not limited to differences in:

  • Determination of medical necessity
  • Limits (e.g. day or visit limits) on covered services
  • Degree to which issuers’ automated claims processing systems routinely deny certain claims
  • Provider knowledge about which claims will be covered and how to properly submit claims
  • Issuer reporting methods, for example, in how to count partial approvals

Depending on the nature of the denial, consumers may or may not be held harmless. If held harmless, a consumer may never realize a claim had been denied, but if not, she could face significant financial liability.

Marketplace insurers denied nearly 1 in 5 in-network claims in 2017. Denials can occur due to improperly submitted or duplicate claims as well as services that the insurer says are not medically necessary On average, issuers reported similar denial rates in earlier years. For the 2016 plan year, healthcare.gov issuers denied 17% of in-network claims, with denial rates of issuers ranging from less than 1% to more than 65%. For the 2015 plan year, the average denial rate was 19%, with denial rates ranging from less than 1% to more than 90%. The claims denial rate was relatively consistent over time for some issuers, while for others it was more variable. For example, Molina Healthcare of Florida reports denying 32% of in-network claims submitted in 2017, 30% in 2016, and 22% in 2015. Meanwhile, Blue Cross Blue Shield of South Carolina reports denying 30% in 2017, 16% in 2016, and 15% in 2015. UPMC Health Plan of Pennsylvania reports denying 4% in 2017, 2016, and 2015. However, Security Health Plan of Wisconsin reports denying 7% of in-network claims in 2017, 8% in 2016, and 35% in 2015.

For the 98 issuers of standalone dental plans in healthcare.gov states that show data on in-network claims submitted and denied in 2017, claims totaled 2.9 million, of which 712,671 (25%) were denied. Nine of the SADP issuers reported denial rates of 10% or less for in-network claims, while 36 issuers reported denial rates of 30% or higher.

Appeals

The ACA transparency data show the number of denied claims that were appealed to the plan (internal appeals), the number of internally appealed denials that were overturned by the issuer, the number of external appeals made by consumers, and the number of externally appealed denials that were overturned. The CMS public use files suppress values lower than 10.

Consumers rarely appeal denied claims. In 2017, 121 major medical issuers show data values on submitted, denied, and appealed in-network claims. Together they denied more than 42 million claims, of which consumers appealed fewer than 200,000 – an appeal rate of less than one-half of one percent (Figure 4). Transparency data for 2015 and 2016 show even lower appeal rates by consumers, 0.1% and 0.2%, respectively.

Issuers uphold the vast majority of denials that are appealed. In 2017, 14% of denials that enrollees appealed internally to their health plans were overturned. The overturn rate of appealed claims denials also varies. Among 118 issuers whose appeals outcomes data were not suppressed, the overturn rate ranged from 1 percent to 88 percent.

Enrollees in healthcare.gov plans appealed less than 1% of denied claims in 2017. About 1 in 7 appeals resulted in a reversal of the original denial

The ACA guarantees external appeal rights to enrollees in all non-grandfathered private health plans. When issuers uphold denials at the internal appeal level, consumers have the option of requesting an independent review by an outside entity, whose decision is binding. Consumers also can bypass internal appeal and go directly to external review in emergencies and certain other circumstances. Consumers seldom avail themselves of external review. Of the 130 issuers that reported data on external appeals requested in 2017, 84 had data suppressed because the number of external appeals filed was less than 10. Even if a value of 9 were assumed for each of the suppressed data fields, fewer than 1 in 11,000 denied claims made it to external review.

Issuers also report data on the disposition of external reviews, though number values for the vast majority have been suppressed. For 2017, 18 issuers display number values for both the number of external appeals filed and the number of denials overturned at external review. For 112 other issuers, either the number of external appeals filed, or the number overturned, or both, was smaller than 10, and thus suppressed. Given these limitations, the data do not support a finding about the percent of denials overturned at external review.

Other Data Sources Provide Context

Absent data on how often other commercial health issuers deny claims, it is difficult to put ACA transparency data in context. The federal government does not yet require ACA transparency data reporting by other insurance issuers or group health plans. In its most recent data collection notice, CMS says it will work with the U.S. Department of Labor and State-based Exchanges to extend transparency data reporting on a phased-in basis after the 2021 collection year.

State insurance regulators collect data on denied claims, appeals, and other metrics from all licensed health issuers in the U.S. under the Market Conduct Annual Statement (MCAS) system, administered by the National Association of Insurance Commissioners. The MCAS health data collection began in 2018 for the 2017 plan year. Data are reported at the plan metal level (i.e., bronze, silver, gold, and platinum) for plans in the individual and small group market, on- and off-exchange. Additional reporting metrics will be added for the 2018 plan year, including reason categories for claims denials, and separate reporting on prior authorizations required for behavioral health and substance use services. MCAS data are collected to inform oversight and market conduct activities and, to date, have not been released to the public.

Meanwhile several other sources of data are available that provide some points of comparison for evaluating the ACA transparency data.4

Covered California

One state-based marketplace – CoveredCA – requires issuers to report data on in-network claims submitted and denied each year. Data are reported at the issuer level and are posted on the marketplace website.  For the 2017 plan year, 10 issuers reported receiving 33 million in-network claims, of which 8 million were denied (24%). The denial rate for individual issuers ranged from 7% to 41% that year. For 2016, 10 issuers reported receiving 24 million claims of which 4 million were denied (18%). Denial rates for issuers ranged from 4% to 33% that year. These metrics and trends are roughly similar to those seen in the ACA transparency data for healthcare.gov issuers. CoveredCA does not post data on appeals.

Connecticut Health Insurance Report Card

Connecticut publishes an annual consumer report card on health insurance carriers. The 2017 report card includes information about 4 HMOs and 8 health issuers that together cover 2.2 million state residents; about 83% of enrollment is from large group plans, 11% from small group plans, and about 6% from individual market plans. The Connecticut report card includes data on all claims submitted and denied, as well as major reasons for claims denials. Data are aggregated and shown at the issuer level.

In 2017, 10 issuers reported receiving 13.8 million claims5 of which 2.2 million (16%) were denied. For specific issuers, the denial rate ranged from 8.5% to 24%. Connecticut issuers also report on certain major reason categories for denied claims. On average, less than 1% of claims denials were on the basis of medical necessity; 9% of denials were because the claim was for a non-covered service; 13% of denials were for duplicate claims; another 13% of denials were because the claimant was not an eligible enrollee or dependent, and 16% of denials were for claims that were incompletely submitted. Reasons were not reported for nearly half of all denials (48.9%), classified in the report card under “all other miscellaneous.”

According to the report card, Connecticut consumers appealed just over 19,000 of the 2.2 million denied claims in 2017, an appeal rate of 0.8%. On average, issuers reversed 39% of denials that were appealed. The 19,000 appeals involved claims denied for every type of reason. On average, appeals of medical necessity denials were reversed by issuers 38% of the time. Issuers were slightly more likely to reverse denials based on claims having been duplicates or submitted incompletely (43% and 44%, respectively), and much less likely to overturn denials based on the claimant not being an eligible enrollee of the plan (15%).6

Medicare Advantage

A recent report by the Inspector General (IG) of the US Department of Health and Human Services examined claims denial rates and appeals in Medicare Advantage plans (ACA transparency data requirements do not apply to the Medicare program). The IG found that, on average, 8% of claims and prior authorizations (combined) submitted to Medicare Advantage plans over a 3-year period (2014-2016) were denied by issuers – less than half the denial rate reported, on average, by healthcare.gov issuers. In addition, the report found that 1% of denied claims were appealed by consumers, and 75% of appeals resulted in overturn of the denial. The IG report also described a 2015 CMS audit of claims denials by Medicare Advantage plans that cited 56% of audited contracts for making inappropriate denials.

Survey of Consumer Experiences

Transparency data provide no information about how claims denials affect patients, though other research sheds some light. A 2000 survey by the Kaiser Family Foundation of consumer experiences with private health insurance found that most consumers (51%) experienced some problem with their coverage. About half of problems related to billing and paperwork issues, while about one-third related to care, and the impact on consumers was often substantial. Almost four in ten consumers (38%) said problems meant they had to pay more for treatment or services. Usually (51%), the financial consequence to the consumer was less than $200, though for some (14%) it was $1,000 or more. Insurance problems were also time consuming; about one-in-five said they lost time from work or school. And they were aggravating; 58% said the experience was as or more stressful than doing their taxes.

Most consumers (88%) took some action to try to resolve problems, most often (77%) by contacting their health plan or provider. Only 6% filed formal appeals. Most consumers (51%) said they either could not resolve the problem to their satisfaction or were still trying. Finally, most people who experienced problems with their health plan (52%) nonetheless gave their plan a satisfaction rating of A or B, though a larger share of consumers who had not experienced any problems (72%) gave their plan an A or B rating.

Discussion

The initial collection and release of ACA transparency data offers a glimpse of what can be known about how health plans work in practice, though limitations raise questions about how to interpret data, what may underlie the results, and how regulators might use transparency data.

The variation in claims denial rates across issuers is striking. Both industry and regulatory experts we spoke to suggested that at least some of the variation is likely due to inconsistencies in how issuers understand reporting instructions,7 what they report, and the accuracy of reporting. For example, issuers may vary in how they report partial claims denials or denials of duplicate claims. Clearer reporting instructions, additional training, and greater use of data verification and validation measures could improve accuracy and consistency of reporting.

Experts also suggested that at least some of the variation in claims denial rates reflects true differences across issuers, and could be better understood if reported in more detail. Differences in the composition of health plan provider networks – for example, networks that are more or less tightly managed, or that include providers who are more or less adept at submitting claims correctly – could underlie some of the variation. CMS announced in a transparency data collection notice that it will require reporting of plan level (versus issuer level) claims data beginning with the 2019 collection year.

Reporting on the reasons for claims denials and other detail about the nature of claims submitted and denied also could inform the transparency data. CMS will require healthcare.gov issuers to report six denial reason categories beginning with the 2019 data collection. The CMS notice specified these categories: (1) referral or prior authorization required, (2) out-of-network, (3) services excluded or not covered, (4) not medically necessary, excluding behavioral health, (5) not medically necessary, behavioral health, and (6) all other.

Reporting on additional metrics could also inform transparency data. Issuers already report data on some additional metrics under other programs. For example, issuers currently submit data on out-of-network claims to state insurance regulators through MCAS, but these data are not yet reported to CMS. Issuers also report on timeliness of claims processing on the MCAS, but not to CMS. In addition, marketplace issuers currently do not report ACA transparency data on pre-authorizations required or denied under marketplace plans, though all licensed issuers do report such information to state regulators through MCAS. Medicare Advantage plans also report separately on claims and prior-authorizations.

For other additional metrics, data reporting is not yet established, and could entail new costs and effort. Some metrics are already specified in federal law, others could fall under the broad authority of the Secretary of Health and Human Services to require reporting on “other information deemed appropriate.”  For example, the ACA specifies transparency data reporting on cost sharing and payments with respect to out-of-network claims. Such data could yield important information about the adequacy of a plan’s provider network; depending on the level of detail required, it could also inform consumers and regulators about the incidence of “surprise” medical bills.8 The effect on patients of claims payment practices and denials is not yet captured in the ACA transparency data. Issuer statements, also called explanation-of-benefits (EOBs), typically do show the patient liability for claims paid, partially paid, or denied, though reporting of this information is not required to date.

The data show that consumers rarely appeal denied health insurance claims, although appeals data are also very limited. For example, data do not show appeals by type of service, or dollar value involved, or based on the reason for the denial. Data on external appeals also do not indicate differences in the type of appeals process applied. Under federal rules, issuers in certain states are subject to a federal appeals process for external review that limits the scope of denials that are eligible for external review and that permits the issuer to determine, on a case-by-case basis, whether to use an external review organization hired by the issuer or by the federal government.9   Data also do not show why the appeals rate is so low. Reasons could include the validity of initial denials, or the inability of patients – especially when sick – to pursue appeals, or deficiencies in consumer notices. For example, a 2015 CMS report on Medicare Advantage plans “cited 45% of contracts for sending denial letters with incomplete or incorrect information, which may have inhibited beneficiaries’ and providers’ ability to file a successful appeal.”10   The ACA established state Consumer Assistance Programs (CAPs), whose duties include helping consumers file appeals for denied claims, and reporting data to the Secretary on consumer experiences with health insurance. Issuers and group health plans are also required to notify consumers about CAPs in their state and include contact information about programs on all written claims denial notices. The CAPs were established in most states in 2010, but Congress has not appropriated funding for the programs since then.

Finally, it remains to be seen how regulators will use transparency data reported by issuers. The stated purpose of MCAS data is to inform oversight and market conduct activities of state regulators. The Inspector General’s report on Medicare Advantage plans finds claims denial rates concerning, “particularly because beneficiaries and providers rarely use the appeals process designed to ensure access to care and payment,” and recommends enhanced oversight by CMS. To date, CMS does not use ACA transparency data in oversight or marketplace plan certification, and its recent data collection notice states this will continue to be the case for another three years. However, in its 2020 proposed rule for marketplace plans, CMS said it will explore opportunities to expand the collection of transparency data in an effort to assist consumers in selecting a QHP offered through the marketplace.

[pmpro_levels]
]]>
https://www.americanpatient.org/claims-denials-and-appeals-in-aca-marketplace-plans/feed/ 0
Despite Health Law’s Protections, Many Consumers May Be ‘Underinsured’ https://www.americanpatient.org/despite-health-laws-protections-many-consumers-may-be-underinsured/?utm_source=rss&utm_medium=rss&utm_campaign=despite-health-laws-protections-many-consumers-may-be-underinsured https://www.americanpatient.org/despite-health-laws-protections-many-consumers-may-be-underinsured/#respond Tue, 24 Oct 2017 02:19:49 +0000 https://www.temp.americanpatient.org/?page_id=1609 Read More]]> By Michelle Andrews,  Kaiser Health News. 

People with chronic conditions will be better protected from crippling medical bills starting in January as the health law’s coverage requirements and spending limits take effect. But a recent analysis by Avalere Health found that many may still find themselves “underinsured,” spending more than 10 percent of their income on medical care, not including premiums, even if they qualify for cost-sharing subsidies on the health insurance marketplaces.

“You have some great protections in place, but these out-of-pocket costs and how plans are structured are going to create some serious problems,” says Marc Boutin, executive vice president at the National Health Council, an advocacy group for people with chronic health conditions.

Potential trouble spots include prescription drugs; specialist care, including that provided by academic medical centers; and services such as physical therapy that typically require a course of treatment over weeks or months, say experts.

The health law prohibits insurers from turning down sick people for coverage and generally eliminates lifetime and annual dollar limits on benefits, including hospitalization and prescription drugs.

It also caps the amount people spend out-of-pocket in 2014 at $6,350 for individuals and $12,700 for families that buy a plan on the individual and small group markets, including the health insurance exchanges. People with incomes below 250 percent of the federal poverty level ($28,725 for an individual or $58,875 for a family of four in 2013) may qualify for cost-sharing subsidies on the marketplaces that reduce those caps as well as their deductibles and copayments.

The Avalere analysis found that many chronically ill people, especially those in Bronze or Silver plans that offer less generous coverage, will likely reach their out-of-pocket maximum every year.

John Earley worries he may be one of them. Earley, 60, has severe plaque psoriasis, a condition that causes painful, itchy red patches on his skin.

After he was diagnosed more than 30 years ago, topical creams and ultraviolet light treatments that slow the growth of skin cells worked for a while. But eventually their effectiveness waned. He finally found relief with Humira, a biologic drug that blocks the production of an immune system protein that causes inflammation. The twice monthly injections cost more than $2,200, but the Texas high-risk pool through which Earley and his wife are insured covers the drug with a $100 copayment. The drug’s manufacturer, AbbVie, covers all but $5 of that amount through its patient assistance program. Their insurance premium is $1,460 per month.

With the Texas high-risk pool set to close early next year, Earley, who works on contract as an architect in Arlington, is checking into plans on the health insurance marketplace. The plan with the best Humira coverage—a $150 copay per refill—is a gold plan with a $1,718 monthly premium for the two of them, says Earley. Plans with lower premiums would require 40 to 50 percent coinsurance for the drug, which is in a high-cost specialty tier.

“What I’m finding with the insurance policies that are available, it’s going to cost you either way,” says Earley.

The gold plan with the best Humira coverage would cost roughly a quarter of their income, says Earley, who is not eligible for tax credits to subsidize his premium costs.  But that may be their best option, even with financial assistance from the drug’s manufacturer, given the high drug coinsurance charges on the other plans.

Drug costs are perhaps the most often cited coverage concern for people with chronic conditions, but there are others, say experts.

Access to specialists and to academic medical centers with the necessary expertise can be problematic on the marketplaces, where many insurers have opted for a narrow network of doctors and hospitals in order to keep a lid on premiums. A recent McKinsey & Co. study found that 70 percent of the 120 plans it examined offered narrow hospital networks that excluded at least 30 percent of an area’s biggest hospitals. Academic medical centers were generally part of broader plans whose premiums were 10 percent higher than average.

For people who need specialist care, narrow networks can be problematic since the law’s limits on what a patient spends out-of-pocket only apply to in-network care. Dermatologists trained in handling severe psoriasis may not be in network, nor the academic medical centers that some people need for treatment, says Leah Howard, director of government relations and advocacy at the National Psoriasis Foundation.

On the other end of the spectrum, sometimes the out-of-pocket costs for effective treatments such as phototherapy can deter patients who would have to make  a copayment for perhaps dozens of sessions.

“We’ve seen people who would prefer to be on phototherapy, but can’t afford $500 in copays over eight weeks, so they end up stepping up to a systemic treatment,” says Howard.

In addition, although dollar limits on benefits aren’t allowed, plans typically limit the number of sessions for certain treatments such as physical therapy.

Because of the rocky rollout of the exchange websites in many states, many consumers have found it difficult to get basic information about premiums and plan deductibles, say experts. Many don’t know which providers are in the plan networks or what benefits the plans cover.

“As more and more people become covered and as people start to use their plans, we’ll see if the cost protections in the plans are sufficient, and directed toward getting people the care they need,” says Sara Collins, a vice president at the Commonwealth Fund.

[pmpro_levels]
]]>
https://www.americanpatient.org/despite-health-laws-protections-many-consumers-may-be-underinsured/feed/ 0
Some Covered California Patients Say They Can’t See A Doctor https://www.americanpatient.org/some-covered-california-patients-say-they-cant-see-a-doctor/?utm_source=rss&utm_medium=rss&utm_campaign=some-covered-california-patients-say-they-cant-see-a-doctor https://www.americanpatient.org/some-covered-california-patients-say-they-cant-see-a-doctor/#respond Thu, 18 Jun 2015 16:22:51 +0000 https://www.temp.americanpatient.org/?p=3943 Read More]]> Consumerwatch, MOUNTAIN VIEW (KPIX 5).

While open enrollment for coverage under the Affordable Care Act is closed, many of the newly insured are finding they can’t find doctors, landing them into a state described as “medical homelessness.”

Rotacare, a free clinic for the uninsured in Mountain View, is dealing with the problem firsthand.

Mirella Nguyen works at the clinic said staffers dutifully helped uninsured clients sign up for Obamacare so they would no longer need the free clinic.

But months later, the clinic’s former patients are coming back to the clinic begging for help. “They’re coming back to us now and saying I can’t find a doctor, “said Nguyen.

Thinn Ong was thrilled to qualify for a subsidy on the health care exchange.  She is paying $200 a month in premiums. But the single mother of two is asking, what for?

“Yeah, I sign it. I got it. But where’s my doctor? Who’s my doctor? I don’t know,” said a frustrated Ong.

Nguyen said the newly insured patients checked the physicians’ lists they were provided and were told they weren’t accepting new patients or they did not participate in the plan.

And Nguyen says – while the free clinic isn’t technically supposed to be treating former patents they signed up for insurance, they can’t in good faith turn them away.

Dr. Kevin Grumbach of UCSF called the phenomenon “medical homelessness,” where patients are caught adrift in a system woefully short of primary care doctors.

“Insurance coverage is a necessary but not a sufficient condition to assure that people get access to care when they need it,” Grumbach said.

Those who can’t find a doctor are supposed to lodge a complaint with state regulators, who have been denying the existence of a doctor shortage for months.

Meanwhile, the sick and insured can’t get appointments.

[pmpro_levels]
]]>
https://www.americanpatient.org/some-covered-california-patients-say-they-cant-see-a-doctor/feed/ 0